跳至主要内容
临床试验/NCT00437853
NCT00437853已完成不适用

Neoadjuvant Hormonal Treatment of Postmenopausal Women Who Have Operable Breast Cancer

Instituto Nacional de Cancerologia de Mexico2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2003年6月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
30
试验地点
2
主要终点
The primary endpoint was to compare overall objective response (OR) determined by clinical (palpation) and ultrasound.

研究概览

简要总结

EFFICACY OF NEOADJUVANT ENDOCRINE THERAPY WITH ANASTROZOLE IN POMENOPAUSAL WOMEN WITH ER-POSITIVE BREAST CANCER.

Flavia Morales-Vásquez, Horacio Noé López Basave.

Background: Neoadjuvant Hormonal Therapy (HT) is being used increasingly to downstage locally advanced and large operable breast cancer. Following this treatment, inoperable breast cancer often becomes fully respectable and tumors requiring mastectomy may be successfully removed by breast-conserving surgery (BCS).

Methods: Recruit postmenopausal women with ER(+) and/or PgR (+) breast cancer (BC) T2,N1-2 to T3,N0-1 were assigned to HT with anastrozole 1 mgr daily for 4 months.

The primary endpoint was to compare overall objective response (OR) determined by clinical (palpation) and ultrasound. Secondary endpoint was the number of patients who qualified for BCS plus radiotherapy.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
66 Years 至 —(Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Postmenopausal women who had primary breast cancer, histological confirmed, through a core needle biopsy, and who{s tumors positive for estrogens receptor ER/PR.
  • Clinical stage IIB or IIIA Tumor assessable by clinical exam, mammogram or and ultrasound Adequate functional bone marrow Documented evidence adequate renal function and liver function Life expectancy for six months Written inform consent

排除标准

  • Prior treatment with letrozole or tamoxifen uncontrol disorders patients with instable angina or uncontrol cardiac disease patient with bilateral breast tumors patients elegies for conservative breast surgery Inflammatory breast cancer o distant metastases Other concurrent malignancies, except carcinoma with in situ cono biopsy of uterine cervix or adequate treat skin cancer no melanoma concomitant cancer treatment such as chemotherapy, immunotherapy biological modulators, endocrinotherapy, biphosphonates therapy and radiotherapy.
  • Concomitant treatment with steroids Others research drug whiting the last 30 days and concomitant use of research drugs History non compliance with medications schedules and patients consider potential unreliable.

结局指标

主要结局

The primary endpoint was to compare overall objective response (OR) determined by clinical (palpation) and ultrasound.

次要结局

  • Secondary endpoint was the number of patients who qualified for BCS plus radiotherapy.

研究者

发起方
Instituto Nacional de Cancerologia de Mexico
申办方类型
Other

研究点 (2)

Loading locations...

相似试验